Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 9Lung Neoplasms 3Neoplasms 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Carboplatin 98Pemetrexed 70pembrolizumab 68Cisplatin 59Paclitaxel 54Docetaxel 45Gemcitabine 37Erlotinib Hydrochloride 24Nivolumab 23osimertinib 17Bevacizumab 17durvalumab 14Cetuximab 13130-nm albumin-bound paclitaxel 13Gefitinib 11Etoposide 11Drug Therapy 11Ipilimumab 9Injections 9Albumin-Bound Paclitaxel 9Vinorelbine 8Radiotherapy 8motexafin gadolinium 7capmatinib 7atezolizumab 7epacadostat 6Taxes 6Cyclophosphamide 6vandetanib 5entinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lung Neoplasms × amrubicin × Clear all
NCT02481830 2023-07-27

CheckMate331

Bristol-Myers Squibb

Phase 3 Completed
569 enrolled 13 charts
Thoracic

Lung Neoplasms

NCT00547651 2019-11-06

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Celgene

Phase 3 Completed
637 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT00660504 2014-07-18

Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer

Sumitomo Pharma (Suzhou) Co., Ltd.

Phase 3 Completed
300 enrolled 10 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡